Investors in Capricor Therapeutics Have Until September 28, 2026 to Join Class Action Lawsuit

Capricor Therapeutics Faces Class Action Lawsuit

Capricor Therapeutics, Inc., a company specializing in cell and exosome-based therapies for treating Duchenne muscular dystrophy, is currently facing allegations of misconduct that have sparked a class action lawsuit. Investors who acquired Capricor securities between December 17, 2025, and July 26, 2026, are encouraged to step forward as lead plaintiffs by the deadline of September 28, 2026.

The Background of the Case

The lawsuit, filed by Robbins Geller Rudman & Dowd LLP, highlights serious allegations against Capricor and its executives, asserting violations of the Securities Exchange Act of 1934. Investors who have experienced significant financial losses during this period have an opportunity to join the action as lead plaintiffs, which could be pivotal as the case unfolds.

Capricor has focused its efforts on developing Deramiocel, a potentially groundbreaking treatment for complications arising from Duchenne muscular dystrophy, a rare genetic disorder marked by muscle degeneration. However, during the class period, Capricor allegedly failed to represent substantial changes made to the pre-specified statistical analysis plan used during clinical trials for Deramiocel. Key changes were reportedly made without the approval of the U.S. Food and Drug Administration (FDA) prior to the resubmission of the Biologics License Application (BLA).

Allegations and Market Impact

The class action lawsuit accuses Capricor of making misleading statements and hiding critical information from investors. Reports indicate that on July 27, 2026, the FDA released briefing documents revealing that Capricor did not disclose the changes to the analysis plan that seemed to cast doubt on the effectiveness of Deramiocel. These documents illustrated that the FDA considered the analytical methods employed to be scientifically unsound, potentially jeopardizing the approval chances for Deramiocel.

Following the FDA's disclosures, Capricor's stock suffered a dramatic drop, plunging 64% in value. This was exacerbated by a non-binding advisory committee vote that came shortly thereafter, resulting in an additional 36% decline in stock price. Investors became increasingly alarmed at the apparent systemic issues within the company’s practices and governance.

The Role of Lead Plaintiffs

The Private Securities Litigation Reform Act of 1995 allows any investor who suffered during the class period to seek the role of lead plaintiff in the ongoing lawsuit. A lead plaintiff, typically the one with the greatest financial interest connected to the case, takes charge of directing the lawsuit and has the authority to choose a law firm for managing the litigation. It is essential to note that joining this process does not affect the ability of other affected shareholders to gain potential recovery.

About Robbins Geller

Robbins Geller Rudman & Dowd LLP has distinguished itself as a leading law firm representing investors in class action lawsuits focused on securities fraud. With a substantial recovery track record, the firm has secured nearly $916 million for investors in 2025 alone and ranks first in securities class action recoveries, reinforcing its reputation in the legal domain.

The Capricor case stands as a critical moment for investors who believe they have been wronged and who are seeking justice in response to what appears to be serious corporate misconduct. Those interested in taking part in the class action lawsuit are urged to act swiftly as the deadline approaches, ensuring that their voices are heard in a matter of paramount importance to their financial futures.

For more information, affected investors can visit Robbins Geller's dedicated page for this class action or consult directly with attorneys from the firm.

Conclusion

The unfolding situation at Capricor Therapeutics highlights the importance of corporate accountability and the need for transparency within the biotechnology sector. Investors must stay informed as the legal proceedings develop, particularly given the implications that this case may have for future regulatory standards and investor protections in the financial marketplace.